The Journal of Pediatrics
Volume 148, Issue 4 , Pages 429-432 , April 2006

Bone loss in children with Crohn disease: Evidence of “osteoimmune” alterations

  • Catherine M. Gordon, MD, MSc

      Affiliations

    • Corresponding Author InformationReprint requests: Catherine M. Gordon, MD, MSc, Division of Endocrinology, Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115.

References 

  1. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology (interplay between the immune system and bone metabolism). Annu Rev Immunol. 2005;Oct 12; Epub. Accessed 1/9/2006
  2. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304–309
  3. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes (possible role of T cells in bone destruction in rheumatoid arthritis patients). Arthritis Rheum. 2001;44:1003–1012
  4. Gordon CM. Evaluation of bone mass in children. Curr Opin Endocrinol Diabetes. 2005;12:444–445
  5. Bachrach LK. Osteoporosis and measurement of bone mass in children and adolescents. Endocrinol Metab Clin North Am. 2005;34:521–535
  6. Sylvester FA, Davis PM, Wyzga N, Hyams JS, Lerer T. Are activated T cells regulators of bone metabolism in children with Crohn disease?. J Pediatr. 2006;148:461–466
  7. Weitzmann MN, Cenci S, Rifas L, Haug J, Dispersio J, Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res. 2001;16:328–337
  8. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature. 1999;397:315–323
  9. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin (a novel secreted protein involved in the regulation of bone density). Cell. 1997;89:309–319
  10. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato E, et al. T-cell mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and INF-γ. Nature. 2000;408:600–605
  11. Smith DD, Gowen M, Mundy GR. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology. 1987;120:2494–2499
  12. Kim S, Koga T, Isobe M, Kern BE, Yokochi T, Chin YE, et al. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev. 2003;17:1979–1991
  13. Chen RM, Chen TL, Chiu WT, Change CC. Molecular mechanism of nitric oxide–induced osteoblast apoptosis. J Orthop Res. 2005;23:462–468
  14. Semaeo EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn’s disease. Inflam Bowel Dis. 1999;5:161–166
  15. Gokhale R, Favus M, Karrison T, Sutton MM, Rick B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114:902–911
  16. Boot AM, Bouquet J, Krenning EP, de Muinick Kezer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 1998;42:188–194
  17. Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, et al. Whole-body BMC in pediatric Crohn disease (independent effects of altered growth, maturation, and body composition). J Bone Miner Res. 2004;19:1961–1968
  18. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The “muscle–bone unit” during the pubertal growth spurt. Bone. 2004;34:771–775
  19. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228–233
  20. Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn’s disease. Aliment Pharmacol Ther. 1998;12:699–705
  21. Sculte C, Dignass AU, Mann K, Goeball H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268–275
  22. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:699–704
  23. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 2004;351:868–875
  24. Bachrach LK. Bare-bones fact (children are not small adults). N Engl J Med. 2004;351:924–926

PII: S0022-3476(06)00062-X

doi: 10.1016/j.jpeds.2006.01.036

The Journal of Pediatrics
Volume 148, Issue 4 , Pages 429-432 , April 2006

Article Tools